Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
Emma Smith(Menzies School of Health Research), Steven Grinspoon(Massachusetts General Hospital), Heather J. Ribaudo(Cancer Research And Biostatistics), Carl J. Fichtenbaum(Cancer Research And Biostatistics), Sarah M Chu(Harvard University), Indira Brar(Henry Ford Hospital), Cristina Gómez‐Ayerbe(Instituto Ramón y Cajal de Investigación Sanitaria), Javier Valencia(Asociación Civil Impacta Salud y Educación), Roger Bedimo(The University of Texas Southwestern Medical Center), Pamela S. Douglas(Duke University), Markella V. Zanni(Harvard University), Michael T. Lu(Cancer Research And Biostatistics), Carlos Malvestutto(The Ohio State University Wexner Medical Center), Gerald S. Bloomfield, Marissa R Diggs(Harvard University), Judith S. Currier(University of California, Los Angeles), Kathleen V. Fitch(Harvard University), Judith A. Aberg(Icahn School of Medicine at Mount Sinai), Maya Watanabe(Cancer Research And Biostatistics), José Valdez Madruga
Cited by 9
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease
|The Journal of Clinical Endocrinology & Metabolism|2007|1.6k